BriaCell CEO Letter to Shareholders
Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization.Successful…
Browsing Tag
BriaCell Therapeutics Corp.
BriaCell Announces New Patent Issuance, Bria-OTS™ IND Timing Guidance, and Additional…
BriaCell’s new patent protects its novel personalized off-the-shelf cell-based technology for breast cancer and multiple other cancer indications until 2040.BriaCell expects to initiate its…
BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in…
BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT™ in combination with Incyte’s retifanlimab in advanced breast cancer. The combination…
BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal
Anti-Cancer activity of BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication. Bria-IMT™, through a novel mechanism…
BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost…
PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
BriaCell Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast…
NEW YORK and VANCOUVER, British Columbia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage…